Semaglutide

Anti-aging, DNA repair, energy metabolism

Anti-aging

DNA Health

Energy

Metabolism

Cognition

NAD+ therapy helps to slow down the aging process by promoting cellular repair, reducing oxidative stress, regulating metabolism and protecting against certain diseases. It also helps to maintain DNA integrity and boosts cellular energy production. Furthermore, NAD+ has shown to improve cognition, concentration and memory retention.

INGREDIENTS

Nicotinamide Adenine Dinucleotide | Saline

RECOMMENDED BOOSTERS

Biotin (5mg)

Glutathione (1000mg)

Zinc (5mg)

DRIP TIME

3-4 hours

HOW TO USE

Recommended regiment is once a week for 10 weeks.

$749 Single Treatment | Preorder Required

BUY NEW

Overview

In the United States alone, hundreds of thousands of deaths every year are attributed to obesity-related diseases. Obesity increases the likelihood of developing other diseases such as diabetes type II, heart disease, cancers, and many other ailments. Two out of three Americans are either overweight or obese. Today, approximately 40% of Americans are considered obese, and it is projected that half of Americans will be obese by 2030. World-wide, the WHO has declared obesity an epidemic since 1997, and the problem has only worsened. However, a recent breakthrough in the treatment of weight loss was discovered. The class of drugs called the glucagon-like peptide-1 receptor agonists, or GLP-1 agonists, has been gaining in popularity for its ability to provide significant weight loss with tolerable or minimal side effects.

Semaglutide is the generic version of the brand-named drugs, Ozempic, Rybelsus, and Wegovy. Semaglutide is in the class of drugs called the glucagon-like peptide-1 receptor agonists, or GLP-1 agonists. GLP-1 agonists work by regulating blood sugar levels and suppresses appetite at a neurological level. Semaglutide and GLP-1’s was originally prescribed for diabetic patients, however, patients on these drugs also reported significant weight loss. Thus, study after study was conducted to assess the safety and efficacy of these drugs for the treatment of obesity. Today, Semaglutide and other GLP-1 agonists are commonly prescribed off-label after repeated confirmation of its efficacy to shed weight, and safety profile.

Why Compounded Semaglutide or Generic Drugs?

Contrary to popular belief and media reports, compounded medications from reputable and vetted compounding pharmacies are safe and effective. They provide the same desired effects as their brand-named counter parts for a fraction of the costs. Currently, there is a massive demand for brand-named GLP-1 agonists, resulting in frequent shortages for patients. Compounded medications fill in those shortage gaps, while providing affordable options for patients.

Who is Semaglutide For?

Individuals who are obese, with a body mass index, or BMI of 30 or more
Patients with a cardiovascular comorbidity, such as high blood pressure, high cholesterol, heart disease, or stroke, and have a BMI of 27 or more, are eligible for treatment.
Diabetics, regardless of obesity, are also eligible for treatment, typically concurrently with other diabetes medications

How is Semaglutide Administered?

Semaglutide is one injection, taken weekly, overs weeks and months for the sustainment of weight loss and treating diabetes. The dosage of the medication is generally increased in the first several months, until a maximum dose is achieved. Your healthcare provide will guide you every step of the way and teach you how to inject yourself with these medications. Semaglutide may also be taken orally as well, but most formularies and prescriptions are given as subcutaneous injections. Subcutaneous injections are administered superficially in a fatty part of the body, such as the belly, buttocks, or back of the arm. Patients that have subcutaneous injectable medications generally have no problem injecting themselves, as it is easy to learn and easy to administer.

What’s The Dosing Schedule Look Like?

Weeks 1-4: 0.25 mg once weekly
Weeks 5-8: 0.5 mg once weekly
Weeks 9-12: 1 mg once weekly
Weeks 13-16: 1.7 mg once weekly
Weeks 17+: 2.4 mg once weekly

Side Effects:

The most common side effect of Semaglutide is gastrointestinal related, occurring in approximately 10% of patients or more. Mild nausea appears to be the most common of the GI side-effects. Loss of appetite is also commonly reported, but likely is more of a “feature” of the drug, attributed to the GLP-1’s mechanism of action to suppress appetite. Diarrhea, abdominal pain, and constipation may also occur with some patients. Most patients report these side effects to dissipate or become milder with time, as the body adjusts during the first steps of titrating the medication. In rare instances, there have been reported gallbladder disease, pancreatitis and kidney injury. It is important to stay hydrated while on GLP-1’s to prevent these issues from occurring. Patients on GLP-1’s must stop their use of the drug if these, and other adverse reactions occur.

Drug Considerations:

AVYIA recommends a comprehensive exercise and nutrition regime when taking Semaglutide and other GLP-1 agonist medications. While significant weight loss is a desired effect, part of that weight lost is from muscle mass unfortunately. Regular strength and weight training maintains proper muscle preservation or growth, while further enhancing fat loss. A diet rich in protein, and sparse in artificial sugars and processed carbohydrates is also recommended while on GLP-1 agonists. Regular exercise and a proper diet further help with weight loss while maintaining lean muscle mass.

Contraindications:

As with any new drug, individuals who have had an allergic reaction, sensitivity, or adverse effect from a prior GLP-1 agonist drug, such as Tirzepatide (Mounjaro), Dulaglutide (Trulicity), Exenatide (Bydureon, Byetta,), Liraglutide (Victoza, Saxenda), Lixisenatide (Adlyxin).
Individuals who currently are suffering from, or have a history of anorexia, bulimia, or other eating disorder that puts them at a nutrient deficiency risk.
Women who are pregnant, or are trying to get pregnant, should not start or be on Semaglutide.
Patients whom have a history, or family history of medullary thyroid cancer or multiple endocrine neoplasia (MEN2), should not start or be on Semaglutide.
Individuals with a body mass index (BMI) of less than 27.
Patients with kidney disease, pancreatitis, gallbladder disease, and diabetic retinopathy.

How Does Semaglutide Compare To Other GLP-1 Agonists?

Compared to Tirzepatide, Semaglutide is lower in month-to-month costs. While both drugs have shown to significantly reduce weight, Tirzepatide is likely to yield more weight loss with similar treatment regimes. In comparative studies, Tirzepatide has shown to have milder side effects. However, most patients on Semaglutide tolerate the already mild GI side effects after a short duration of treatment

Bioavailability:

Subcutaneous: 89%
Oral 0.4% to 1.0%